Daiichi Sankyo Company, Limited announced the appointment of new Group corporate officers effective from April 1, 2019. The appointments are: Katsumi Fujimoto as Member of the Board; Toshiaki Tojo as "Member of the Board Senior Executive Officer In charge of Vaccine Business and Quality & Safety Management "; Masahiko Ohtsuki as "Executive Officer Vice President of Business Development & Licensing Dept. "; Junichi Fukute as "Executive Officer Head of Supply Chain Div. "; Takeshi Hamaura as "Executive Officer Head of Pharmaceutical Technology Div. "; Shoji Hirashima as "Executive Officer Head of Global Brand Strategy Div. "; Ryoichi Watanabe as "Corporate Officer In charge of Internal Audit Dept. "; Hironobu Furuta as "Corporate Officer Head of Corporate Affairs Div. "; Koji Ogawa as "Corporate Officer Head of US Corporate Div., Daiichi Sankyo Inc. "; Seiichiro Kumakura as " Corporate Officer Vice President of Research Function, R &D Div. "; Takashi Fukuoka as " Corporate Officer Executive Vice President, R&D Affairs, Daiichi Sankyo Inc. "; Hironobu Saito as " Corporate Officer Vice President of Oncology Clinical Development Dept., Oncology Function, R &D Div. "; Wataru Takasaki as "Corporate Officer Head of R&D Div. and Vice President of Oncology Function "; Tomoji Hashiba as "Corporate Officer Vice President of Kyushu Branch, Sales & Marketing Div. "; and Miyuki Arai as "Corporate Officer Head of Quality & Safety Management Div.".